305 results on '"Daniel P. Judge"'
Search Results
302. 075: Cardiac safety and tolerability, and effects on cardiac function of tafamidis in patients with non-V30M TTR-FAP
- Author
-
Karine Berthet, Violaine Planté-Bordeneuve, Ahmet Dogan, Daniel P. Judge, Thibaud Damy, and Michel Slama
- Subjects
Cardiac function curve ,Tafamidis ,medicine.medical_specialty ,Ejection fraction ,biology ,business.industry ,Cardiomyopathy ,medicine.disease ,Transthyretin ,chemistry.chemical_compound ,chemistry ,Tolerability ,Heart failure ,Internal medicine ,Troponin I ,biology.protein ,medicine ,Cardiology ,cardiovascular system ,business ,Cardiology and Cardiovascular Medicine - Abstract
Background Transthyretin familial amyloid polyneuropathy (TTR-FAP) is an autosomal dominant disease characterized by extracellular amyloid deposition in the nerves and heart. Orthotopic liver transplant (OLT) is recommended to remove the source of mutated TTR and stop amyloid deposition. However, progressive cardiomyopathy due to continuing amyloidosis has been described following OLT in patients with non-V30M mutations. Tafamidis prevents dissociation of TTR into monomers and formation of amyloid. Objectives To evaluate cardiac safety and tolerability of tafamidis in patients with non-V30M TTR-FAP. Methods Patients (N=21) with TTR-FAP due to non-V30M TTR mutations and no OLT history were studied in a phase 2 open-label trial. Cardiac assessments included ECG, 24-hour Holter monitoring, echocardiogram, and cardiac biomarkers (troponin I and NT-pro-BNP) at baseline and 6 and 12 months. Results Of the 21 patients enrolled, mean (SD) age, LVEF, troponin I, and NT-pro-BNP at baseline were 63.1 (9.86) years, 60.3 (9.96)%, 0.023(0.04) ng/mL, and 1248.9 (1529.4) pg/mL, respectively. Nine patients had a history of cardiac events. Six of these 9 experienced peripheral edema or dyspnea related to heart failure while on treatment, and 3 patients were hospitalized for other cardiovascular events (AV block, coronary stenosis, TIA). Eighteen patients completed the study, with no significant changes in troponin I, LVEF, or cardiac remodeling. NT-pro-BNP, while elevated at baseline, remained stable with no clinically relevant changes. The pattern of Holter monitoring abnormalities was similar at baseline and while on treatment (eg, atrial tachycardia, 52.4% [11/21] vs 44.4% [4/9]). The percentage of patients with normal heart rate variability (HRV) increased from 21% (4/19) at baseline to 42% (8/19) at month 12. Discussion This study showed no deleterious effects of tafamidis on cardiac function among a cohort of treated TTR-FAP patients. The number of patients with normal HRV improved. Conclusion Tafamidis was safe and well tolerated in patients with non-V30M TTR-FAP.
- Full Text
- View/download PDF
303. Heart Failure and Genomics
- Author
-
Nicole M. Johnson, Allison L. Cirino, Daniel P. Judge, and Carolyn Y. Ho
- Subjects
medicine.medical_specialty ,business.industry ,Heart failure ,medicine ,Genomics ,Cardiology and Cardiovascular Medicine ,Intensive care medicine ,medicine.disease ,business - Abstract
We applaud the efforts by Drs. Donahue, Marchuk, and Rockman to review the current utility of genomics in heart failure ([1][1]). As they noted, this is a complex and developing field both in cardiology and in other medical specialties, with great potential to enhance our ability to diagnose and
- Full Text
- View/download PDF
304. Tnni3k alleles influence ventricular mononuclear diploid cardiomyocyte frequency.
- Author
-
Peiheng Gan, Michaela Patterson, Alexa Velasquez, Kristy Wang, Di Tian, Jolene J Windle, Ge Tao, Daniel P Judge, Takako Makita, Thomas J Park, and Henry M Sucov
- Subjects
Genetics ,QH426-470 - Abstract
Recent evidence implicates mononuclear diploid cardiomyocytes as a proliferative and regenerative subpopulation of the postnatal heart. The number of these cardiomyocytes is a complex trait showing substantial natural variation among inbred mouse strains based on the combined influences of multiple polymorphic genes. One gene confirmed to influence this parameter is the cardiomyocyte-specific kinase Tnni3k. Here, we have studied Tnni3k alleles across a number of species. Using a newly-generated kinase-dead allele in mice, we show that Tnni3k function is dependent on its kinase activity. In an in vitro kinase assay, we show that several common human TNNI3K kinase domain variants substantially compromise kinase activity, suggesting that TNNI3K may influence human heart regenerative capacity and potentially also other aspects of human heart disease. We show that two kinase domain frameshift mutations in mice cause loss-of-function consequences by nonsense-mediated decay. We further show that the Tnni3k gene in two species of mole-rat has independently devolved into a pseudogene, presumably associated with the transition of these species to a low metabolism and hypoxic subterranean life. This may be explained by the observation that Tnni3k function in mice converges with oxidative stress to regulate mononuclear diploid cardiomyocyte frequency. Unlike other studied rodents, naked mole-rats have a surprisingly high (30%) mononuclear cardiomyocyte level but most of their mononuclear cardiomyocytes are polyploid; their mononuclear diploid cardiomyocyte level (7%) is within the known range (2-10%) of inbred mouse strains. Naked mole-rats provide further insight on a recent proposal that cardiomyocyte polyploidy is associated with evolutionary acquisition of endothermy.
- Published
- 2019
- Full Text
- View/download PDF
305. A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome
- Author
-
Jefferson J Doyle, Alexander J Doyle, Nicole K Wilson, Jennifer P Habashi, Djahida Bedja, Ryan E Whitworth, Mark E Lindsay, Florian Schoenhoff, Loretha Myers, Nick Huso, Suha Bachir, Oliver Squires, Benjamin Rusholme, Hamid Ehsan, David Huso, Craig J Thomas, Mark J Caulfield, Jennifer E Van Eyk, Daniel P Judge, Harry C Dietz, GenTAC Registry Consortium, and MIBAVA Leducq Consortium
- Subjects
aortic aneurysm ,Marfan syndrome ,protein kinase C ,ERK ,calcium channel blocker ,Amlodipine ,Medicine ,Science ,Biology (General) ,QH301-705.5 - Abstract
Calcium channel blockers (CCBs) are prescribed to patients with Marfan syndrome for prophylaxis against aortic aneurysm progression, despite limited evidence for their efficacy and safety in the disorder. Unexpectedly, Marfan mice treated with CCBs show accelerated aneurysm expansion, rupture, and premature lethality. This effect is both extracellular signal-regulated kinase (ERK1/2) dependent and angiotensin-II type 1 receptor (AT1R) dependent. We have identified protein kinase C beta (PKCβ) as a critical mediator of this pathway and demonstrate that the PKCβ inhibitor enzastaurin, and the clinically available anti-hypertensive agent hydralazine, both normalize aortic growth in Marfan mice, in association with reduced PKCβ and ERK1/2 activation. Furthermore, patients with Marfan syndrome and other forms of inherited thoracic aortic aneurysm taking CCBs display increased risk of aortic dissection and need for aortic surgery, compared to patients on other antihypertensive agents.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.